Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade

We determined whether prostate specific antigen (PSA) would decrease with immediate antiandrogen switching from bicalutamide (BCL) to flutamide (FLT) in patients receiving combined androgen blockade for advanced prostate cancer. From 2002 to 2006, 20 patients who showed PSA failure after first-line hormonal therapy with a luteinizing hormone-release hormone (LH-RH) agonist and BCL were enrolled. All patients were immediately switched from BCL to FLT, administered with an LH-RH agonist, as second-line combined androgen blockade (CAB). We evaluated the PSA response to second-line CAB. Eight patients (40%) were responsive, showing PSA decreases of at least 50%. The median (range) duration of the PSA response was 18.4 (3–26) months. Second-line CAB using FLT was effective in 40% of patients who received first-line CAB using BCL. The lower Gleason scores at the initial prostate biopsy probably reflect the response to second-line CAB. Responders showed significantly better OS and CSS in the determination of any PSA decline and 40% PSA decline. The median OS duration in nonresponders and responders (40% PSA decline) was 1433 days versus 3617 days. It is concluded that an immediate switch from BCL to FLT is effective for some CRPC patients after first-line CAB using BCL.

[1]  K. Nishimura,et al.  Effects of flutamide as a second‐line agent for maximum androgen blockade of hormone refractory prostate cancer , 2007, International journal of urology : official journal of the Japanese Urological Association.

[2]  Y. Mizutani,et al.  Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first‐line hormonal therapy , 2007, International journal of urology : official journal of the Japanese Urological Association.

[3]  I. McEwan,et al.  Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. , 2005, Molecular endocrinology.

[4]  H. Miyake,et al.  Clinical outcome of maximum androgen blockade using flutamide as second‐line hormonal therapy for hormone‐refractory prostate cancer , 2005, BJU international.

[5]  P. Kantoff,et al.  Efficacy of nilutamide as secondary hormonal therapy in androgen‐independent prostate cancer , 2005 .

[6]  P. Kantoff,et al.  Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. , 2005, BJU international.

[7]  D. McDonnell,et al.  Androgen receptor-cofactor interactions as targets for new drug discovery. , 2005, Trends in pharmacological sciences.

[8]  E. Messing,et al.  Androgen deprivation therapy for prostate cancer: Current status and future prospects , 2004, The Prostate.

[9]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[10]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[11]  D. Tindall,et al.  Mechanisms of androgen-refractory prostate cancer. , 2004, The New England journal of medicine.

[12]  K. Akakura,et al.  Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. , 2004, The Journal of urology.

[13]  H. Miyamoto,et al.  Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer , 2003, The Prostate.

[14]  T. Ichikawa,et al.  Androgen receptor involvement in the progression of prostate cancer. , 2003, Endocrine-related cancer.

[15]  W. Kassouf,et al.  Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. , 2003, The Journal of urology.

[16]  S. Kato,et al.  Stabilization of androgen receptor protein is induced by agonist, not by antagonists. , 2002, Biochemical and biophysical research communications.

[17]  C. Heinlein,et al.  Androgen receptor (AR) coregulators: an overview. , 2002, Endocrine reviews.

[18]  W. Stadler,et al.  Nilutamide: possible utility as a second-line hormonal agent. , 2001, Urology.

[19]  T. Bishop,et al.  Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. , 2001, Journal of medicinal chemistry.

[20]  P. Schellhammer,et al.  Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. , 1997, The Journal of urology.

[21]  Mcleod,et al.  Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer. , 1997, The oncologist.

[22]  E. Wilson,et al.  Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. , 1996, Urology.

[23]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[24]  M. Levell,et al.  SUPPRESSION OF PLASMA ANDROGENS BY THE ANTIANDROGEN FLUTAMIDE IN PROSTATIC CANCER PATIENTS TREATED WITH ZOLADEX, A GnRH ANALOGUE , 1990, Clinical endocrinology.

[25]  B. Djavan,et al.  Androgen deprivation therapy. , 2008, Reviews in urology.

[26]  T. Matsuda,et al.  Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. , 2004, Japanese journal of clinical oncology.

[27]  Hideo Araki,et al.  Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. , 2003, Cancer research.

[28]  R L Vessella,et al.  Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .